Page 6 - Read Online
P. 6
Cancer Drug Resistance
CONTENTS
Topic: Papers from the BACR Conference-Response and Resistance in
Cancer Therapy
1 What really matters - response and resistance in cancer therapy
Tim R. Fenton, Michelle D. Garrett, Mark N. Wass, Martin Michaelis
Cancer Drug Resist 2018;1:200-203 http://dx.doi.org/10.20517/cdr.2018.19
2 Meeting Abstracts of the BACR conference: response and resistance in cancer therapy
Tim R. Fenton, Michelle D. Garrett, Martin Michaelis, Mark N. Wass
Cancer Drug Resist 2018;1:266-302 http://dx.doi.org/10.20517/cdr.2018.18
3 Resistance to ERK1/2 pathway inhibitors; sweet spots, fitness deficits and drug addiction
Matthew J. Sale, Kathryn Balmanno, Simon J. Cook
Cancer Drug Resist 2019;2:365-380 http://dx.doi.org/10.20517/cdr.2019.14
4 Glutaminase inhibition in renal cell carcinoma therapy
Aleksandra M. Raczka, Paul A. Reynolds
Cancer Drug Resist 2019;2:356-364 http://dx.doi.org/10.20517/cdr.2018.004
5 Targeting MYCN and ALK in resistant and relapsing neuroblastoma
Elizabeth R Tucker, Evon Poon, Louis Chesler
Cancer Drug Resist 2019;2:803-812 http://dx.doi.org/10.20517/cdr.2019.009
6 Drug-adapted cancer cell lines as preclinical models of acquired resistance
Martin Michaelis, Mark N. Wass, Jindrich Cinatl
Cancer Drug Resist 2019;2:447-456 http://dx.doi.org/10.20517/cdr.2019.005
